Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/365—Lactones
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/02—Antineoplastic agents specific for leukemia

Definitions

• This invention generally relates to medicine and pharmacology.
• methods for treating and ameliorating a cancer, or recurrence of a cancer comprising administration to an individual in need thereof a pharmaceutical composition comprising 17S-FD-895 (also known as rebecsinib) and a second drug such as an ATP-competitive protein tyrosine kinase inhibitor such as fedratinib or dasatinib.
• a cancer such as acute myeloid leukemia (AML)
• a pharmaceutical composition comprising 17S-FD-895 (also known as rebecsinib) and a second drug such as an ATP-competitive protein tyrosine kinase inhibitor such as fedratinib or dasatinib.
• MPN myeloproliferative neoplasm
• AML stem cell propagation comprising administration to an individual in need thereof a pharmaceutical composition comprising 17S-FD-895 (rebecsinib) and a second drug.
• pre-LSC pre-leukemia stem cell
• LSCs leukemia stem cells
• CSCs cancer stem cells
• MDS myeloproliferative neoplasms
• AML acute myeloid leukemia
• CLL chronic lymphocytic leukemia
• MM multiple myeloma
• compositions, formulations or therapeutic combinations of drugs comprising:
• rebecsinib also called 17S-FD-895, or an enantiomer, stereoisomer, deuterated version, or salt thereof;
• the cancer is a leukemia
• the cancer is acute myeloid leukemia (AML), myeloproliferative neoplasm (MPN), myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and/or multiple myeloma (MM);
• AML acute myeloid leukemia
• MPN myeloproliferative neoplasm
• MDS myelodysplastic syndrome
• AML acute myeloid leukemia
• CLL chronic lymphocytic leukemia
• MM multiple myeloma
• MPN myeloproliferative neoplasm
• pre-LSC pre-leukemia stem cell transformation into leukemia stem cells
• RNA-1 RNA-1 - the in vivo inhibition of splicesomes in AML or MPN, and/or - the in vivo inhibition of transcript binding to a component of a spliceosome binding pocket or binding to AD ARI (adenosine deaminase acting on RNA-1), comprising: administration to an individual in need thereof a formulation, a pharmaceutical composition or a therapeutic combination of drugs, comprising:
• rebecsinib also called 17S-FD-895, or an enantiomer, stereoisomer, deuterated version, or salt thereof, or
• (b) a compound of (a), or rebecsinib or 17S-FD-895, and at least one second drug.
• 17S-FD-895 are administered once a day for between one to two weeks, twice a week for 2 weeks or between about one to two weeks, followed by 2 weeks rest or 2 to 4 weeks rest, with a duration of two, three, four, five or six cycles, optionally with a duration of four 28 day or monthly cycles, or the pharmaceutical or therapeutic compositions, formulations or therapeutic combinations of drugs are formulated for this dosage administration;
• the at least one second drug comprises an ATP-competitive protein tyrosine kinase inhibitor, wherein optionally the ATP-competitive protein tyrosine kinase inhibitor comprises dasatinib (or SPRYCELTM or DASANIXTM);
• the at least one second drug comprises a JAK2 (Janus kinase 2) inhibitor, optionally fedratinib (or INREBICTM), or fedratinib and at least one second drug, wherein optionally the fedratinib is dosaged at 60 mg/kg twice daily orally, optionally for one to two or more weeks;
• the at least one second drug comprises a chemotherapeutic agent
• the chemotherapeutic agent comprises one, two, three or more of: afatinib (or GILOTRIFTM), afuresertib, alectinib, alisertib, alvocidib, amsacrine, amonafide, amuvatinib, axitinib, azacitidine, azathioprine, bafetinib, barasertib, bendamustine, bleomycin, bosutinib, bortezomib, busulfan, cabozantinib, camptothecin, canertinib, capecitabine, cabazitaxel, carboplatin, carmustine, cenisertib, ceritinib, chlorambucil, cisplatin, cladribine, clofarabine, crenolanib, criz
• the at least one second drug comprises a hypomethylating agent (HMA), wherein optionally the HMA comprises azacitidine (or VID AZATM) or decitabine (or DACOGENTM);
• HMA hypomethylating agent
• the HMA comprises azacitidine (or VID AZATM) or decitabine (or DACOGENTM);
• the at least one second drug comprises a second telomerase inhibitor
• the telomerase inhibitor comprises at least one, two or three of: imetelstat, zidovudine (or azidothymidine (AZT)), stavudine (or ZERITTM), tenofovir or tenofovir disoproxil (or VIREADTM), didanosine (or VIDEXTM), abacavir (ZIAGENTM), TMPI, telomestatin, RHPS4, BRACO-19, TMPyP4, tertom otide, ASTVAC-1, GX-301, UCPVax, UV-1, Vx-001, Vx-006, ING-1400, INVAC-1, ASTVAC-2, Telin(ab 4,4-dichloro-l-(2,4-dichlorophenyl)-3-methyl-5- pyrazolone), Vbx-011, Vbx-021, Vbx-026INO-5401
• the formulation, pharmaceutical composition or therapeutic combination of drugs or an active agent or drug contained therein is or are formulated or contained in: a liquid formulation (optionally sterile saline or water), a spray, a powder, an aerosol, a mist, or any formulation for inhalation, a pill, a capsule, a tablet, or a geltab, or equivalents; or, are coated on the surface of or contained in: a bead, a powder, a particle, or a multilayered bead or particle, and optionally the bead, powder, particle or the multilayered bead or particle is contained in a pill, a capsule, a tablet, or a geltab, or equivalents, for oral delivery, wherein optionally the pill, capsule, tablet, geltab or equivalent for oral delivery is a hard gelatin capsule or equivalent, or comprises a hard gelatin or equivalent; or, a drug delivery device or package, blister pack, clamshell or tray comprising a plurality of compartments spatially arranged on the drug delivery device or
• an active agent used in methods as provided herein, or a drug in the formulation, pharmaceutical composition or therapeutic combination of drugs as provided herein is dosaged at between about 10 to 500 mg/day, or between about 500 to 1 gram a day, or at a dosage of between about 100 to 600 mg per day or per dosage, or at about 100, 200, 300, 400, 500 or 600 mg per day or per dosage, and optionally a unit dosage is administered to an individual in need thereof once a day (QD), or twice a day (BID), or three times a day (TID), or more;
• an active agent used in methods as provided herein, or a drug in the formulation, pharmaceutical composition or therapeutic combination of drugs as provided herein is administered as or formulated with or formulated as an) inhaled or aerosol formulation such as a powder or a mist or aerosol, and/or is formulated with or formulated as an oral, intramuscular (IM), subcutaneous (SC), intrathecal or intravenous (IV) formulation, wherein optionally both the inhaled (or aerosol) and the oral, IV, SC, intrathecal and/or IM formulations are administered simultaneously or sequentially;
• IM intramuscular
• SC subcutaneous
• IV intravenous
• an active agent used in methods as provided herein, or a drug in the formulation, pharmaceutical composition or therapeutic combination of drugs as provided herein, is or are administered to an individual in need thereof: using a drug delivery device, optionally by inhalation, wherein the drug delivery device optionally comprises an inhalation device or inhaler or a nasal spray device, and optionally the inhaler or a nasal spray device is a hand-held inhaler or a nasal spray device, and optionally the inhaler or a nasal spray device is a metered or dose-counting inhaler or a nasal spray device, or intravenously (IV) or intramuscularly (IM).
• a drug delivery device optionally by inhalation
• the drug delivery device optionally comprises an inhalation device or inhaler or a nasal spray device
• the inhaler or a nasal spray device is a hand-held inhaler or a nasal spray device
• the inhaler or a nasal spray device is a metered or dose-counting inhaler or a nasal spray device,
• compositions, formulations or therapeutic combinations comprising 17S-FD-895 (or rebecsinib), or 17S-FD-895 and at least one second drug, for use in:
• the cancer is a leukemia
• the cancer is acute myeloid leukemia (AML), myeloproliferative neoplasm (MPN), myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and/or multiple myeloma (MM);
• AML acute myeloid leukemia
• MPN myeloproliferative neoplasm
• MDS myelodysplastic syndrome
• AML acute myeloid leukemia
• CLL chronic lymphocytic leukemia
• MM multiple myeloma
• MPN myeloproliferative neoplasm
• AML stem cell propagation or
• pre-LSC pre-leukemia stem cell transformation into leukemia stem cells
• compositions, formulations or therapeutic combinations comprising 17S-FD-895 (or rebecsinib), or 17S-FD-895 and at least one second drug, for use in the manufacture of a medicament or a pharmaceutical composition for:
• the cancer is a leukemia
• the cancer is acute myeloid leukemia (AML), myeloproliferative neoplasm (MPN), myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and/or multiple myeloma (MM);
• AML acute myeloid leukemia
• MPN myeloproliferative neoplasm
• MDS myelodysplastic syndrome
• AML acute myeloid leukemia
• CLL chronic lymphocytic leukemia
• MM multiple myeloma
• MPN myeloproliferative neoplasm
• AML stem cell propagation or
• pre-LSC pre-leukemia stem cell
• LSCs leukemia stem cells
• RNA-1 the in vivo inhibition transcript binding to a component of a spliceosome binding pocket or binding to AD ARI (adenosine deaminase acting on RNA-1).
• FIG. 1A-F illustrate that rebecsinib (17S-FD-895) significantly inhibited human CD34+Lin- (hCD34 + ) cell engraftment in secondary AML patient 50261 (sAML50261) transplanted NSG-SGM3 mouse models that secrete human stem cell factor, GM-CSF and IL-3:
• FIG. 1 A graphically illustrates the percentage of engrafted human CD45+ (hCD45+) cells in the peripheral blood of immunocompromised mice transplanted with secondary AML patient 37 (sAML37PB) after treatment with vehicle control, fedratinib, rebecsinib (17S-FD-895) or a combination of fedratinib and rebecsinib (17S-FD-895);
• FIG. IB graphically illustrates % CD45 positive (human CD45+ (hCD45+) cells in the spleens of sAML transplanted mice (sAML37SP) mice after treatment with vehicle control, fedratinib, rebecsinib (17S-FD-895) or a combination of fedratinib and rebecsinib (17S-FD-895); and
• FIG. 1C graphically illustrates % human CD45 positive cells (hCD45+) in the bone marrow of secondary AML patient 37 transplanted mice (sAML37BM) after treatment with vehicle control, fedratinib, rebecsinib (17S-FD-895) or a combination of fedratinib and rebecsinib (17S-FD-895);
• FIG. ID graphically illustrates % CD34 positive, Lin negative, cells (CD34+ (hCD34 + Lin”) cells in mice transplanted with secondary AML patient 37 peripheral blood (sAML37PB) after treatment with vehicle control, fedratinib, rebecsinib (17S- FD-895) or a combination of fedratinib and rebecsinib (17S-FD-895);
• FIG. IE graphically illustrates % CD34 positive Lineage negative cells (hCD34 + Lin‘ cells) in the spleens of secondary AML patient 37 (AML37SP) transplanted mice after treatment with vehicle control, fedratinib, rebecsinib (17S-FD- 895) or a combination of fedratinib and rebecsinib (17S-FD-895); and,
• FIG. IF graphically illustrates % CD34 positive Lineage negative cells (hCD34+) in bone marrow of secondary AML patient 37 transplanted mice (sAML37BM) after exposure to vehicle control, fedratinib, rebecsinib (17S-FD-895) or a combination of fedratinib and rebecsinib (17S-FD-895); where all p values were calculated using an unpaired T test.
• FIG. 2 graphically illustrates that spleen size in combination treatment groups is significantly smaller following primary transplantation, showing spleen weight in mg in secondary AML patient 37 transplanted (sAML37) NSG-SGM3 mice that secrete human stem cell factor, GM-CSF and IL-3 after treatment with vehicle control, fedratinib, rebecsinib (17S-FD-895) or a combination of fedratinib and rebecsinib (17S-FD-895); where all p values were calculated using an unpaired T test.
• FIG. 3 graphically illustrates a reduction in serially transplantable leukemia stem cells (LSC) as indicated by a significant decrease in the spleen size of RAG2-/- gc-/- mice that were engrafted with human cells from mice that had been treated with a combination of fedratinib and rebcsinib compared to groups treated with control, fedratinib or rebecsinib (17S-FD-895).
• LSC serially transplantable leukemia stem cells
• live human CD45+ cells from secondary AML patient number 50261 (sAML 50261) engrafted mice were serially transplanted into RAG2-/-gc-/- mice that lack T, B and NK cells following treatment with vehicle control, fedratinib, rebecsinib (17S-FD-895) or a combination of fedratinib and rebecsinib (17S-FD-895); where all p values were calculated using an unpaired T test.
• FIG. 4, FIG. 5 and FIG. 6A-C illustrate targeted inhibition of leukemia stem cells with rebecsinib (17S-FD-895), where: rebecsinib inhibits leukemia stem cells (LSC) and reduces AML burden at doses that spare normal hematopoietic stem cells (HSC) in vivo, LSC areakily sensitive to splicing modulation with Rebecsinib in vivo and, splice isoform biomarkers include SF3B1, MCL1, CD44 and AD ARI : FIG.
• HSC human cord blood hematopoietic stem cell
• FIG. 5 graphically illustrates leukmia stem cell (LSC) survival based on the frequency of live CD34 positive, CD38 positive, Lin negative progenitor cells (% baseline) after administering: vehicle or rebecsinib; where p value was calculated using an unpaired T test;
• LSC leukmia stem cell
• FIG. 6A graphically illustrates SF3B1 splicing factor intronic retention by showing SF3B1 intron 2/total expression ratio after administering: vehicle or rebecsinib; where p value was calculated using an unpaired T test;
• FIG. 6B graphically illustrates MCL1 levels by showing expression relative to a housekeeping gene, HPRT, after administering: vehicle or rebecsinib; where p value was calculated using an unpaired T test; and
• FIG. 6C graphically illustrates CD44-012 levels by showing expression relative to HPRT, after administering: vehicle or rebecsinib; where p value was calculated using an unpaired T test.
• FIG. 7, FIG. 8 and FIG. 9 illustrate that the lentiviral MAPT-GFP/RFP splicing reporter reveals intron retention following rebecsinib treatment, and flow cytometry shows decreased ADAR pl 50 splice isoform expression following rebecsinib treatment:
• FIG. 7 illustrates an image AD ARI pl 50 positive live cells, inset shows 100 pm measure
• FIG. 8 graphically illustrates the ratio of RFP (MFI) to GFP (MFI) after administering DMSO vehicle control and 100 nM rebecsinib; where p value was calculated using an unpaired T test; and
• FIG.9 graphically illustrates an AD ARI Pl 50 flow cytometry of an absolute count of AD ARI Pl 50 positive live cells after administering DMSO vehicle control and 100 nM rebecsinib; where p value was calculated using an unpaired T test.
• FIG. 10, FIG. 11, FIG. 12, FIG. 13, FIG. 14, FIG. 15 and FIG. 16 illustrate that inflammatory cytokine signaling drives AD ARI pl 50 protein induced splicing alterations, and rebecsinib (17S-FD-895) inhibits high-risk myelofibrosis hematopoietic progenitor cell (HPC) survival at doses that inhibit AD ARI activity by AD ARI nanoluciferase reporter assay:
• FIG. 10 schematically illustrates the effect of APOBEC3C on pre-LSC cells, and the effect of ADAR pl 50 on LSC cells;
• FIG. 11 graphically illustrates rebecsinib inhibits ADARl-pl50 in a dose dependent manner as shown by qRT-PCR, showing relative mRNA expression normalized to human HPRT after administering none (control), or varying levels of rebecsinib;
• FIG. 12 graphically illustrates that rebecsinib inhibits AML patient number 193 (AML 193) progenitor ADARlpl50 protein levels in a dose dependent manner as shown by flow cytometry, showing amounts of ADARlpl50 mean fluorescent intensity (MFI) live cells normalized to DMSO control after exposure to varying amounts of rebecsinib;
• AML 193 AML patient number 193
• ADARlpl50 mean fluorescent intensity
• FIG. 13 graphically illustrates that rebecsinib inhibits AD ARI nano-luciferase reporter activity at ImicroM in high-risk myelofibrosis progenitors, showing, using a AD ARI nano-luciferase reporter, relative luciferase units normalized to cell viability after administering DMSO control, or 1 pM rebecsinib;
• FIG. 14 graphically illustrates that rebecsinib inhibits myelofibrosis progenitor clonogenic (HPC) capacity showing CD34 positive, CD38 positive, cells after administering DMSO control, or 1 pM rebecsinib;
• HPC myelofibrosis progenitor clonogenic
• FIG. 15 graphically illustrates that rebcsinib inhibits AD ARI reporter activity in HPC progenitors at 1 microM rebecsinib levels, showing ADAR-1 pl 50 MFI live Lin negative, and ; and CD34 positive, CD38 positive, cells after administering DMSO control, or 1 pM rebecsinib; and,
• FIG. 16 graphically illustrates that rebcsinib alters splicing reporter activity in high risk myelofibrosis (hrMF) in samples with high AD ARI expression, showing RFP MFI live lineage CD34 positive, CD38 positive, cells after administering DMSO control, or 1 pM rebecsinib.
• FIG. 17 illustrates an IVIS imaging of AD ARI Nano-luciferase-GFP (ADARl-nano-luc) reporter activity marks normal aged human hematopoietic stem cell engraftment in RAG2-/-gc-/- mice transplanted intrahepatically at birth and imaged at 22 weeks post-transplantation.
• FIG. 18 illustrates an IVIS imaging of AD ARI nano-luc reporter stably transduced triple negative breast cancer cells (MDA-MB-231) injected into the cerebral ventricles of newborn RAG2-/-g c-/- mice engraft in the brain and spinal cord.
• AD ARI Nano-luciferase-GFP ADARl-nano-luc
• FIG. 19 illustrates an IVIS imaging at 6 weeks post-transplantation intrahepatically in newborn RAG2-/-g c-/- mice with AD ARI nano-luc reporter stably transduced triple negative breast cancer cells (100,00 MDA-MB-231 cells per mouse).
• FIG. 20 schematically illustrates an exemplary method for making 17S-FD- 895 (rebecsinib).
• FIG. 21 A schematically illustrates that the synthesis of 17S-FD-895 (1) arises through the coupling of side chain 2 and core 3; and that the 11 sp3 stereocenters and stereochemistry of the three olefins of 1 arose from 12 precursors (inset) that are available on the kilogram scale.
• FIG. 2 IB schematically illustrates a retro-analysis of the related macrolide, pladienolide B; shaded/colored highlights denote the sourced components as shown in gray (middle) inset.
• FIG. 22A-E, FIG. 23 A-F and FIG. 24 A-E graphically illustrate flow cytometric analysis plots of ADARl-nano-luc-GFP reporter expression (Y-axis) and CD44-APC (a breast cancer stem cell marker) on the X-axis in:
• FIG. 22A-C liver and spinal cord cells
• FIG. 23 A-F peripheral blood (PB), spleen (SP) and bone marrow (BM), and
• FIG. 24A-E spinal cord and brain, showing engraftment in the spinal cord but not the brain following intrahepatic as opposed to cerebral ventricle transplantation.
• FIG. 25A-B graphically illustrate stromal co-culture assays in sAML (splicing factor mutated versus unmutated) and high-risk myelofibrosis (MF) versus aged-matched normal bone marrow (a-NBM) samples treated with 17S- FD-895:
• FIG. 26A-B graphically illustrate in vitro stromal co-culture and protein expression assays in lentiviral AD ARI reporter- transduced myelofibrosis (MF) samples treated with rebecsinib, where intracellular flow cytometry -based quantification of AD AR Ip 150 protein expression (FIG. 26A) and STAT3 phosphorylation (FIG. 26B) is shown, as expressed by mean fluorescence intensity, MF/, values within FIPC populations; Statistical analyses were performed using two-sided pair-wise t-test; Error bars represent means +/- SEM.
• FIG. 27A-D graphically illustrate AD ARI expression and activity, and prosurvival transcript expression, in AML cells treated with Rebecsinib in vitro:
• FIG. 27A graphically illustrates total AD ARI mRNA expression in lentiviral-shCtrl or shADARl -transduced AML-193 cells treated with 17S-FD-895 or DMSO control;
• FIG. 27B graphically illustrates RNA editing activity on the endogenous LSC- associated transcript AZINI quantified by RNA-editing site-specific-qPCR (RESSqPCR) in AML-193 cells treated with 17S-FD-895 or DMSO control for 4 (left panel) or 24 (right panel) hours (hrs);
• RESSqPCR RNA-editing site-specific-qPCR
• FIG. 27C graphically illustrates splice isoform-specific qPCR showing reduced MCL1-L expression after AD ARI knockdown and/or 17S treatment for 4 (left panel) or 24 (right panel) hrs;
• FIG. 28A-E graphically illustrate 17S-FD-895 treatment in lentiviral splicing reporter assays, where KGla or MOLM13 human adult leukemia cells were stably transduced with the pCDH-EF l a-lRES-Puro MAPT splicing reporter lentiviral vector:
• FIG. 28A-B graphically illustrate intron retention (FIG. 28A) and viability of KG- la (FIG. 28B) cells treated with 17S-FD-895 for 24 hrs;
• a leukemia such as acute myeloid leukemia (AML)
• AML acute myeloid leukemia
• a pharmaceutical composition comprising 17S-FD-895 (also called rebecsinib), and optionally a second drug such as an ATP-competitive protein tyrosine kinase inhibitor such as fedratinib or dasatinib.
• a second drug such as an ATP-competitive protein tyrosine kinase inhibitor such as fedratinib or dasatinib.
• provided are methods for the in vivo inhibition of myeloproliferative neoplasm (MPN) or AML stem cell propagation comprising administration to an individual in need thereof a pharmaceutical composition comprising 17S-FD-895 (rebecsinib), or 17S-FD-895 and second drug.
• methods for the in vivo inhibition preleukemia stem cell (pre-LSC) transformation into leukemia stem cells (LSCs) comprising administration to an individual in need thereof a pharmaceutical composition comprising 17S-FD-895 (rebecsinib), or 17S-FD-895 and second drug.
• 17S-FD-895 significantly reduces the frequency of self-renewing CSCs in MPN, MDS and both adult and pediatric AML stromal co-cultures as well as in humanized AML mouse models at doses that spare normal hematopoietic stem cell (HSC; CD34+Lin-) survival and differentiation into mature progeny.
• HSC normal hematopoietic stem cell
• 17S-FD-895 and related compounds reduce malignant regenerating potential in vitro and in vivo by impairing CSC self-renewal capacity while sparing normal human hematopoietic stem and progenitor cells (HSPCs).
• HSPCs normal human hematopoietic stem and progenitor cells
• Splicing modulators such as E7107, H3B-8800 and 17S-FD-895 (rebecsinib), have efficacy in pre-clinical models of leukemia but only 17S-FD-895 is stable, safe and well tolerated in pre-clinical models. While one chemically distinct splicing modulator, E7107, entered clinical trials for solid tumors (Hong 2014), two of 26 patients developed reversible optic neuritis (Leon 2017) related to compound instability and resulting in early trial discontinuation. Subsequent analysis suggested that ocular toxicity was related to metabolic decomposition of E7107 to a seco-acid. In contrast, the candidate 17S-FD-895 undergoes metabolic decomposition, but without toxic consequences.
• 17S-FD-895 offers the potential to evaluate splicing modulators in a clinical setting without liabilities associated with compound instability and unoptimized pharmacology.
• E7107 showed limited efficacy in clinical trial results (Hong, 2014) whereas there is a significant reduction in AML CSC survival and self-renewal after treatment with 17S- FD-895 in preclinical models.
• 17S-FD-895 modulates splicing of several BCL2 prosurvival family members, including BCL2, MCL1, and BCL- XL (BCL2L1).
• BCL2L1 splice isoform switching contributes to LSC generation (Goff et al., 2013) and is of particular relevance to the unique mechanism of action (MO A) of 17S-FD-895 in sAML because its transcripts have been shown to be resistant to another splicing modulatory agent that previously entered clinical trials, E7107 (Aird et al., Nature Communications 2019).
• sAML CSC upregulate the splicing regulatory gene ACINI (Crews et al., 2016), which regulates production of BCL2L1 (BCL-XL) in the exon junction complex (EJC) (Michelle et al., 2012).
• BCL-XL BCL2L1
• EJC exon junction complex
• MCL1L is overexpressed in high risk MPNs and MDS, sAML, pediatric AML, and multiple myeloma.
• IL-6ST, ADARlpl50 and STAT3beta splice isoforms are overexpressed during MDS and MPN progression to AML.
• hematologic malignancies may be particularly sensitive to splicing modulator treatment with 17S-FD-895 due to intrinsic activation of these pro-survival and selfrenewal promoting isoforms in CSC, and subsequent modulation by 17S-FD-895.
• Quantification of CSC-specific and splicing modulator-responsive transcripts will facilitate rapid screening of in vivo sensitivity of different tissues to splicing modulation and identification of doses that exhibit minimal effects on normal tissues compared with malignant cell types.
• H3B-8800 is a splicing factor mutation-dependent splicing modulatory agent.
• the most common mutations observed were in RNA splicing factors SF3B1, U2AF1, SRSF2 (88% of patients).
• SRSF2 RNA splicing factor mutation-dependent splicing modulatory agent.
• SF3B1, U2AF1, SRSF2 88% of patients.
• CR or PR there was no CR or PR observed in the trial showing a lack of efficacy with this splicing modulator.
• 17S-FD-895 17S-FD-895 (Kumar 2016) as a stable, well- tolerated FD-895 analog that is spliceosome mutation independent.
• 17S-FD-895 (rebecsinib) is based on extensive in vitro and in vivo pre-clinical studies showing stability, safety, tolerability and human CSC-targeting efficacy in humanized models of AML.
• 17S-FD-895 has a favorable safety profile with no ocular toxicity, as determined by a board certified ophthalmologist, observed in rats, rabbits and monkey toxicity studies.
• 17S-FD-895 has a favorable potency and therapeutic index compared to other splicing modulators in that it reduces disease regenerating potential in in vitro and in vivo by impairing CSC self-renewal capacity while sparing normal human HSPC.
• 17S-FD-895 has a clinically tractable formulation and pharmacological (PK/PD) properties with favorable bioavailability and stability that enables twice weekly intravenous dosing regimens that eliminate human CSCs. Sensitive and selective methods to predict and monitor response to splicing modulator therapy with 17S-FD-895 will be essential to the future clinical development of these agents.
• PK/PD pharmacological
• 17S- FD-895 inhibits transcript binding to SF3B 1 and other components of the spliceosome binding pocket, including SF3B3 and PHF5A, which perturbs generation of key CSC survival transcripts, thereby inducing effective elimination of CSCs in AML samples regardless of splicing factor mutational status.
• H3B-8800 splicing modulatory agent
• H3B-8800 which is dependent on splicing factor mutations, such as SRSF2, for altering its RNA binding preference within the spliceosome and efficacy (https://ashpublications.org/blood/article/134/Supplement_l/673/426543/Results-of- a-Clinical-Trial-of-H3B-8800-a- Splicing).
• Biomarkers were developed and validated to monitor responses to splicing modulation in human and rat cells.
• the transcripts selected for species-specific primer design included MCL1, BCL-XL, CD44, PTK2B, DNAJB1, and the SF3B family. Together, these biomarkers are diagnostic tools to predict and monitor response to splicing modulator treatment.
• 17S-FD-895 (rebecsinib) can be made using any protocol known in the art, for example, as described in Chan et al., Cell Reports Physical Science 1 : see FIG. 21, and as described in FIG. 22A-B:
• FIG. 21 A schematically illustrates that the synthesis of 17S-FD-895 (1) arises through the coupling of side chain 2 and core 3.
• FIG. 2 IB schematically illustrates a retro-analysis of the related macrolide, pladienolide B, as developed by Ghosh and Anderson from core 5a and Kotake from core 5b. Shaded/colored highlights denote the sourced components as shown in gray (middle) inset.
• compositions comprising drugs, and therapeutic combinations of drugs, and formulations, and liposomes, for practicing methods and uses as provided herein to treat or ameliorate a cancer, for example, to treat or ameliorate a cancer, wherein optionally the cancer is a leukemia, and optionally the cancer is acute myeloid leukemia (AML), myeloproliferative neoplasm (MPN), myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and/or multiple myeloma (MM); or can be used for in vivo inhibition of myeloproliferative neoplasm (MPN) or AML stem cell propagation; or can be used for the in vivo inhibition pre-leukemia stem cell (pre-LSC) transformation into leukemia stem cells (LSCs), or can be used for the in vivo inhibition of splicesomes in AML or MPN, and/
• a formulation or pharmaceutical compositions used to practice methods and uses as provided herein can be administered parenterally, topically, orally or by local administration, such as by aerosol or transdermally, or intravitreal injection.
• the formulations and pharmaceutical compositions can be formulated in any way and can be administered in a variety of unit dosage forms depending upon the condition or disease and the degree of illness, the general medical condition of each patient, the resulting preferred method of administration and the like. Details on techniques for formulation and administration are well described in the scientific and patent literature, see, for example, the latest edition of Remington's Pharmaceutical Sciences, Maack Publishing Co., Easton PA (“Remington’s”).
• these compositions used to practice methods and uses as provided herein are formulated in a buffer, in a saline solution, in a powder, an emulsion, in a vesicle, in a liposome, in a nanoparticle, in a nanolipoparticle and the like.
• the compositions can be formulated in any way and can be applied in a variety of concentrations and forms depending on the desired in vivo, in vitro or ex vivo conditions, a desired in vivo, in vitro or ex vivo method of administration and the like. Details on techniques for in vivo, in vitro or ex vivo formulations and administrations are well described in the scientific and patent literature.
• Formulations and/or carriers used to practice methods or uses as provided herein can be in forms such as tablets, pills, powders, capsules, liquids, gels, syrups, slurries, suspensions, etc., suitable for in vivo, in vitro or ex vivo applications.
• formulations and pharmaceutical compositions used to practice methods and uses as provided herein can comprise a solution of compositions (for example, any active agent as used in methods provided herein) disposed in or dissolved in a pharmaceutically acceptable carrier, for example, acceptable vehicles and solvents that can be employed include water and Ringer's solution, an isotonic sodium chloride.
• acceptable vehicles and solvents that can be employed include water and Ringer's solution, an isotonic sodium chloride.
• sterile fixed oils can be employed as a solvent or suspending medium.
• any fixed oil can be employed including synthetic mono- or diglycerides, or fatty acids such as oleic acid.
• solutions and formulations used to practice methods and uses as provided herein are sterile and can be manufactured to be generally free of undesirable matter. In one embodiment, these solutions and formulations are sterilized by conventional, well known sterilization techniques.
• solutions and formulations used to practice methods and uses as provided herein can comprise auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, toxicity adjusting agents, for example, sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate and the like.
• concentration of active agent in these formulations can vary widely, and can be selected primarily based on fluid volumes, viscosities and the like, in accordance with the particular mode of in vivo, in vitro or ex vivo administration selected and the desired results.
• compositions and formulations used to practice methods and uses as provided herein can be delivered by the use of liposomes.
• liposomes particularly where the liposome surface carries ligands specific for target cells (for example, an injured or diseased neuronal cell or CNS tissue), or are otherwise preferentially directed to a specific tissue or organ type, one can focus the delivery of the active agent into a target cells in an in vivo, in vitro or ex vivo application.
• target cells for example, an injured or diseased neuronal cell or CNS tissue
• nanoparticles, nanolipoparticles, vesicles and liposomal membranes comprising compounds used to practice methods and uses as provided herein, for example, to deliver compositions used to practice methods as provided herein, for example, to deliver a drug or drugs, for example to treat or ameliorate a cancer
• the cancer is a leukemia
• the cancer is acute myeloid leukemia (AML), myeloproliferative neoplasm (MPN), myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and/or multiple myeloma (MM); or can be used for in vivo inhibition of myeloproliferative neoplasm (MPN) or AML stem cell propagation; or can be used for the in vivo inhibition pre-leukemia stem cell (pre-LSC) transformation into leukemia stem cells (LSCs), or can be used for the in vivo
• pre-LSC pre-
• multilayered liposomes comprising compounds used to practice methods and uses as provided herein, for example, as described in Park, et al., U.S. Pat. Pub. No. 20070082042.
• the multilayered liposomes can be prepared using a mixture of oil-phase components comprising squalane, sterols, ceramides, neutral lipids or oils, fatty acids and lecithins, to about 200 to 5000 nm in particle size, to entrap a composition used to practice methods and uses as provided herein.
• Liposomes can be made using any method, for example, as described in Park, et al., U.S. Pat. Pub. No. 20070042031, including method of producing a liposome by encapsulating an active agent (for example, a drug combination as provided herein, or a AD ARI -encoding nucleic acid, or a AD ARI polypeptide), the method comprising providing an aqueous solution in a first reservoir; providing an organic lipid solution in a second reservoir, and then mixing the aqueous solution with the organic lipid solution in a first mixing region to produce a liposome solution, where the organic lipid solution mixes with the aqueous solution to substantially instantaneously produce a liposome encapsulating the active agent; and immediately then mixing the liposome solution with a buffer solution to produce a diluted liposome solution.
• an active agent for example, a drug combination as provided herein, or a AD ARI -encoding nucleic acid, or a AD ARI polypeptide
• liposome compositions used to practice methods and uses as provided herein comprise a substituted ammonium and/or polyanions, for example, for targeting delivery of a compound (for example, a drug or drug combination as provided herein) to a desired cell type (for example, a cancer cell), as described for example, in U.S. Pat. Pub. No. 20070110798.
• a compound for example, a drug or drug combination as provided herein
• a desired cell type for example, a cancer cell
• nanoparticles comprising compounds (for example, a drug or drug combination as provided herein) in the form of active agent-containing nanoparticles (for example, a secondary nanoparticle), as described, for example, in U.S. Pat. Pub. No. 20070077286.
• nanoparticles comprising a fat-soluble active agent or a fat-solubilized water-soluble active agent to act with a bivalent or trivalent metal salt.
• solid lipid suspensions can be used to formulate and to deliver compositions used to practice methods and uses as provided herein to mammalian cells in vivo, for example, to the CNS, as described, for example, in U.S. Pat. Pub. No. 20050136121.
• any delivery vehicle can be used to practice the methods or uses as provided herein, for example, to deliver compositions (for example, a drug or drug combination as provided herein) in vivo, to an individual in need thereof.
• delivery vehicles comprising polycations, cationic polymers and/or cationic peptides, such as polyethyleneimine derivatives, can be used for example as described, for example, in U.S. Pat. Pub. No. 20060083737.
• a dried polypeptide-surfactant complex is used to formulate a composition used to practice methods as provided herein, for example as described, for example, in U.S. Pat. Pub. No. 20040151766.
• a composition used to practice methods and uses as provided herein can be applied to cells using vehicles with cell membrane-permeant peptide conjugates, for example, as described in U.S. Patent Nos. 7,306,783; 6,589,503.
• the composition to be delivered is conjugated to a cell membrane-permeant peptide.
• the composition to be delivered and/or the delivery vehicle are conjugated to a transport-mediating peptide, for example, as described in U.S. Patent No. 5,846,743, describing transport-mediating peptides that are highly basic and bind to poly-phosphoinositides.
• a drug or drug combination as provided herein is delivered in vivo using methods as provided herein formulated in a lipid formulation or a liposome and injected for example intramuscularly (IM), for example using formulations and methods as described in U.S. patent application no.
• IM intramuscularly
• lipid nanoparticle that comprises: noncationic lipids comprise a mixture of cholesterol and DSPC, or a PEG-lipid, or PEG- modified lipid, or LNP, or an ionizable cationic lipid; or a mixture of (13Z,16Z)-N,N- dimethyl-2-nonylhenicosa-12,15-dien-l-amine, cholesterol, DSPC, and PEG-2000 DMG.
• the PEG-lipid is 1,2-Dimyristoyl-sn-glycerol methoxypolyethylene glycol (PEG-DMG), PEG-disteryl glycerol (PEG-DSG), PEG- dipalmetoleyl, PEG-dioleyl, PEG-distearyl, PEG-diacylglycamide (PEG-DAG), PEG- dipalmitoyl phosphatidyl ethanolamine (PEG-DPPE), or PEG- 1,2- dimyristyloxlpropyl-3 -amine (PEG-c-DMA), or, the PEG-lipid is PEG coupled to dimyristoylglycerol (PEG-DMG).
• PEG-DMG 1,2-Dimyristoyl-sn-glycerol methoxypolyethylene glycol
• PEG-DSG PEG-disteryl glycerol
• PEG-DAG PEG- dipalmetoleyl
• the LNP comprises 20-99.8 mole % ionizable cationic lipids, 0.1-65 mole % non-cationic lipids, and 0.1- 20 mole % PEG-lipid.
• the LNP comprises an ionizable cationic lipid selected from the group consisting of (2S)-l-( ⁇ 6-[(3))-cholest-5-en-3- yloxy]hexyl ⁇ oxy)-N,N-dimethyl-3-[(9 Z)-octadec-9-en-l-yloxy]propan-2-amine;
• the PEG modified lipid comprises a PEG-modified phosphatidylethanolamine, a PEG- modified phosphatidic acid, a PEG-modified ceramide, a PEG-modified dialkylamine, a PEG-modified diacylglycerol, a PEG-modified dialkylglycerol, and mixtures thereof.
• the ionizable cationic lipid comprises: 2,2- dilinoleyl-4-dimethylaminoethyl-[l,3]-di oxolane (DLin-KC2-DMA), dilinoleyl- methyl-4-dimethylaminobutyrate (DLin-MC3-DMA), di((Z)-non-2-en-l-yl) 9-((4- (dimethylamino)butanoyl)oxy) heptadecanedioate (L319), (13Z,16Z)-N,N-dimethyl- 3 -nonyldocosa- 13,16-dien- 1 -amine, (12Z, 15Z)-N,N-dimethyl-2-nonylhenicosa- 12,15- dien-l-amine, and N,N-dimethyl-l-[(l S,2R)-2-octylcyclopropyl]h
• the lipid is ( 13Z,16Z)-N, N-dimethyl-3 -nonyldocosa- 13,16-dien- 1 -amine or N,N-dimethyl-l-[(l S,2R)-2-octylcyclopropyl]heptadecan-8-amine, each of which are described in PCT/US2011/052328, the entire contents of which are hereby incorporated by reference.
• a non-cationic lipid of the disclosure comprises l,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2- dioleoyl-sn-glycero-3 -phosphoethanolamine (DOPE), l,2-dilinoleoyl-sn-glycero-3- phosphocholine (DLPC), 1,2-dimyristoyl-sn-gly cero-phosphocholine (DMPC), 1,2- dioleoyl-sn-glycero-3 -phosphocholine (DOPC), l,2-dipalmitoyl-sn-glycero-3- phosphocholine (DPPC), 1,2-diundecanoyl-sn-gly cero-phosphocholine (DUPC), 1- palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2-di-O-octadecenyl-sn
• DOPC
• DOPG 1.2-dioleoyl-sn-glycero-3-phospho-rac-(l -glycerol) sodium salt
• DOPG 1.2-dioleoyl-sn-glycero-3-phospho-rac-(l -glycerol) sodium salt
• DOPG 1.2-dioleoyl-sn-glycero-3-phospho-rac-(l -glycerol) sodium salt
• sphingomyelin or mixtures thereof.
• compositions, drug combinations and formulations used to practice methods and uses as provided herein can be administered for prophylactic and/or therapeutic treatments, for example, to treat or ameliorate a cancer, wherein optionally the cancer is a leukemia, and optionally the cancer is acute myeloid leukemia (AML), myeloproliferative neoplasm (MPN), myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and/or multiple myeloma (MM); or can be used for in vivo inhibition of myeloproliferative neoplasm (MPN) or AML stem cell propagation; or can be used for the in vivo inhibition pre-leukemia stem cell (pre-LSC) transformation into leukemia stem cells (LSCs), or can be used for the in vivo inhibition of splicesomes in AML or MPN, and/or can be used for the in vivo inhibition of transcript binding to a component
• the amount of pharmaceutical composition adequate to accomplish this is defined as a "therapeutically effective dose.”
• the dosage schedule and amounts effective for this use i.e., the “dosing regimen,” will depend upon a variety of factors, including the stage of the disease or condition, the severity of the disease or condition, the general state of the patient's health, the patient’s physical status, age and the like. In calculating the dosage regimen for a patient, the mode of administration also is taken into consideration.
• compositions, drug combinations and formulations used to practice methods and uses as provided herein can be administered as a single dosage or in multiple dosages, as needed.
• these dosages are administered intravitreally, orally, IM, IV, or intrathecally.
• the vectors are delivered as formulations or pharmaceutical preparations, for example, where the drug or drugs are contained in a nanoparticle, a particle, a micelle or a liposome or lipoplex, a polymersome, a polyplex or a dendrimer.
• these dosages are administered once a day, once a week, or any variation thereof as needed to maintain in vivo expression levels of a desired drug, which can be monitored by assessing the therapeutic effect, for example, to treat, ameliorate, protect against, reverse or decrease the severity or duration of a cancer.
• the dosage regimen also takes into consideration pharmacokinetics parameters well known in the art, i.e., the active agents’ rate of absorption, bioavailability, metabolism, clearance, and the like (see, for example, Hidalgo-Aragones (1996) J. Steroid Biochem. Mol. Biol. 58:611-617; Groning (1996) Pharmazie 51 :337-341; Fotherby (1996) Contraception 54:59-69; Johnson (1995) J.
• compositions used to practice methods as provided herein are in a daily amount of between about 0.1 to 0.5 to about 20, 50, 100 or 1000 or more z/g per kilogram of body weight per day.
• dosages are from about 1 mg to about 4 mg per kg of body weight per patient per day are used.
• Lower dosages can be used, in contrast to administration orally, into the blood stream, into a body cavity or into a lumen of an organ.
• Substantially higher dosages can be used in topical or oral administration or administering by powders, spray or inhalation.
• Actual methods for preparing parenterally or non-parenterally administrable formulations will be known or apparent to those skilled in the art and are described in more detail in such publications as Remington's, supra.
• the methods as provided herein can further comprise co-administration with other drugs or pharmaceuticals, for example, compositions for treating any neurological or neuromuscular disease, condition, infection or injury, including related inflammatory and autoimmune diseases and conditions, and the like.
• the methods and/or compositions and formulations as provided herein can be co-formulated with and/or co-administered with, fluids, antibiotics, cytokines, immunoregulatory agents, anti-inflammatory agents, pain alleviating compounds, complement activating agents, such as peptides or proteins comprising collagen-like domains or fibrinogen-like domains (for example, a ficolin), carbohydrate-binding domains, and the like and combinations thereof.
• products of manufacture and kits for practicing methods as provided herein can further comprise instructions for practicing methods as provided herein. Any of the above aspects and embodiments can be combined with any other aspect or embodiment as disclosed here in the Summary, Figures and/or Detailed Description sections.
• the term “about” is understood as within a range of normal tolerance in the art, for example within 2 standard deviations of the mean. About (use of the term “about”) can be understood as within 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12% 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.05%, or 0.01% of the stated value. Unless otherwise clear from the context, all numerical values provided herein are modified by the term “about.”
• the terms “substantially all”, “substantially most of’, “substantially all of’ or “majority of’ encompass at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 99.5%, or more of a referenced amount of a composition.
• Example 1 Exemplary Methods Using 17S-FD-895 to reduce self-renewing AML CSCs and for targeted CSC eradication
• Test System In vitro cell line assays under treatment with 17S-FD-895 (InM- lOuM ranges).
• human leukemia cell lines KG-la, MOLM-13, and HL-60
• rat leukemia lines RBL-1
• Cells were harvested for RNA extraction and processed for qRT-PCR with splice isoform-specific primers designed to recognize intron retention or exon-skipping events in species-specific transcripts of SF3B family members, MCL-1, and other sAML-specific splice variants.
• Test Article 17S-FD-895 (research and pre-pilot batches #IA01f and IKOlf).
• Control Article ⁇ 0.5% DMSO.
• Test and Control Article Preparation Test articles were thawed at room temperature from stock aliquots stored in glass vials at -80C in 100% DMSO at a concentration of Img/mL. Immediately upon thawing, Test Articles were diluted directly into tissue culture media for final treatment at a concentration of luM for single dose studies, or at a range from lOOnM-lOuM for dose response studies. For vehicle controls, 100% DMSO was diluted directly into tissue culture media at the same dilutions as the Test Article solution.
• a selective splicing modulator, 17S-FD-895, and related compounds exhibit disease-modifying, on-target efficacy against cancer stem cells in diverse human cancer models.
• CSCs cancer stem cells
• 17S-FD- 895 novel splicing modulator
• Splicing modulation with 17S-FD-895 significantly reduces secondary acute myeloid leukemia (sAML) CSC burden in vivo with a reduction in sAML CSC survival and self-renewal.
• 17S-FD-895 spares normal human hematopoietic progenitor cells in vivo and 17S-FD-895 eradicates human CSC, independent of mutation status.
• 17S-FD-895 meets a pressing unmet medical need for developing splicing modulator therapy to eradicate CSCs thereby preventing AML therapeutic resistance and relapse.
• 17S-FD-895 binds within the spliceosome adjacent to SF3B1, SF3B3, and PHF5A. Treatment with 17S-FD-895 increases intron retention and exon skipping thereby reducing survival and self-renewal of CSC.
• on-target splicing modulatory effects including in pro-survival MCL1L transcripts, and splicing factor gene products such as SF3B1 and SF3B3, which form part of the splicing modulator binding pocket as well as alterations in selfrenewal promoting AD ARI and STAT3beta transcripts.
• targeted CSC eradication as well as unique intron-retained and exon-skipped transcripts that can be quantified by splice isoform-specific qRT- PCR, a novel lentiviral splicing reporter assay, and RNA-sequencing analyses and can be used as predictive biomarkers to monitor molecular responses to 17S-FD-895 treatment.
• a subset of these transcripts can only be detected after exposure to a splicing modulator, and their generation precedes cytotoxic effects in cells, thus enabling quantification of relative sensitivity and predicting response to splicing modulation.
• these molecular tools provide a sensitive method of detecting activity and mechanism of action of 17S-FD-895, and demonstrate CSC selectivity of 17S-FD-895 in humanized stromal co-cultures and humanized CSC mouse models, which will have utility in future clinical development of this class of therapeutic agents.
• lentiviral splicing reporter in human AML CSC for in vitro splicing modulator treatment and detection of intron retention in live cells.
• primary, human AML CSC we first transduced human AML CSC (CD34+ cells) with the lentiviral fluorescence splicing reporter.
• human AML CSC CD34+ cells
• 17S-FD-895 there was increased intron retention following 17S- FD- 895 treatment.
• These biomarker studies provide evidence of on-target molecular responses to splicing modulator treatment that can be rapidly quantified and monitored in human cells isolated from leukemia-engrafted animal tissues, suggesting the potential utility of these molecular assays as companion biomarkers in the clinical setting.
• mice a dose of 10 mg/kg in mice is sufficient to reduce in vivo sAML CSC burden while sparing normal HSPC development.
• No evidence of Test Article-related toxicity was observed after 2 weeks of dosing at 10 or 20mg/kg in a humanized in vivo model of normal HSPC development.
• Our biomarker system confirmed a functional and molecular therapeutic index for 17S-FD-895, whereby sAML CSC are more sensitive to splicing modulation than normal HSPC and their progeny.
• RNAseq of highly purified non-leukemic or AML hematopoietic stem cells (HSCs; CD34+CD38-Lin-) and hematopoietic progenitor cells (HPCs; CD34+CD38+Lin-) from pediatric bone marrow or peripheral blood.
• HSCs highly purified non-leukemic or AML hematopoietic stem cells
• HPCs hematopoietic progenitor cells
• MCL1-L The pro-survival splice variant, MCL1-L, of the BCL2 family was shown to be highly expressed in pediatric AML progenitors via RNA sequencing and significantly increased via qRT-PCR between CD34+ cord blood and pediatric AML samples.
• HSCs show both decreased expression levels of RBFOX2 and MBNL1 and MBNL2, while AML derived HPCs suggest antagonistic coregulation of splicing by RBFOX2 and CELF2.
• Cytogeneics 46, XX, 1 ,inv(3 )(q21 q26.2), del(5)(q 14q34), der( 12 )t( 1 ; 1 2)(q21;pl l.2),20,+r,+marl [9]/46,sl,der(7)t(7;9)(pl3;ql3)[4]/46,sl,i(21)(ql0)[3 ]/46,sl, add(2)(q31)[2]/46,sl,add(2)(q33)[2]
• Cytogeneics unbalanced translocation (1;6) with Iq gain, 6p loss; loss of 20q (in 4% of cells).
• rebecsinib 17S- FD-895 significantly inhibited CD34+Lin- cells in sAML50261 transplanted NSG- SGM3 mouse models.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Epidemiology (AREA)
• Organic Chemistry (AREA)
• Oncology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Hematology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicinal Preparation (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Priority Applications (7)

Applications Claiming Priority (2)

Publications (1)

Family

ID=82654982

Family Applications (1)

Country Status (7)

Cited By (2)

Citations (12)

Family Cites Families (3)

• 2022
  • 2022-02-01 WO PCT/US2022/014663 patent/WO2022165398A1/en not_active Ceased
  • 2022-02-01 CA CA3206959A patent/CA3206959A1/en active Pending
  • 2022-02-01 EP EP22746855.0A patent/EP4284519A4/en active Pending
  • 2022-02-01 CN CN202280012882.6A patent/CN116829142A/zh active Pending
  • 2022-02-01 US US18/275,388 patent/US20240148688A1/en active Pending
  • 2022-02-01 AU AU2022214463A patent/AU2022214463A1/en active Pending
  • 2022-02-01 JP JP2023546266A patent/JP2024506847A/ja active Pending
• 2025
  • 2025-01-31 JP JP2025015025A patent/JP2025065209A/ja active Pending

Patent Citations (13)

Non-Patent Citations (26)

Also Published As

Similar Documents

Legal Events